Posted: 4 September 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations from its bioMUSE natural history study of Multiple…
Posted: 4 September 2023 Universal Biosensors, Inc. (ASX: UBI) is pleased to announce it has received approval from the Indian Central Drugs Standard Control Organisation (CDSCO) for the sale of Xprecia Prime, with the first order received from…
Posted: 4 September 2023 Clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the U.S. Department of Defence (DOD) to support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator…
Posted: 4 September 2023 An existing blood cancer drug has shown promise in killing ‘silent’ HIV cells and delaying reinfections – a significant pre-clinical discovery that could lead to a future cure for the disease. Hidden HIV cells,…
Posted: 31 August 2023 A tablet taken once a day could be a new treatment used to target one of the key drivers of cancer. Research, published in this month’s New England Journal of Medicine, has shown that divarasib,…
Posted: 29 August 2023 Avecho has received firm commitments to raise $6M via a Placement to support a landmark clinical study testing its proprietary TPM®-enhanced CBD soft-gel capsule for the treatment of insomnia. The Placement was conducted on the same…
Posted: 29 August 2023 As the second phase of the BioMedTech Horizons (BMTH) program moves to completion, a new report has captured the outcomes of the 38 innovations supported through the program. Launched in May 2017, the BMTH…
Posted: 29 August 2023 MTPConnect and Pathology Technology Australia (PTA) have today released an Action Plan for establishing an end-to-end sovereign manufacturing capability for diagnostic products in Australia and strengthening supply chain resilience. The Action Plan makes a…
Posted: 25 August 2023 WEHI researchers Associate Professor Tim Thomas and Professor Anne Voss have won the 2023 UNSW Eureka Prize for Scientific Research for their pioneering work on a novel approach to cancer treatment. The prize recognises their groundbreaking research in…
Posted: 25 August 2023 How has your winter been? Have you managed to avoid illness like Covid-19, the flu or respiratory viruses associated with the common cold? Over at Firebrick Pharma (ASX:FRE), it’s spent the winter watching its Phase…
Posted: 25 August 2023 4DMedical’s unique XV Technology™ has propelled a team of medical researchers to a 2023 Eureka Prize win, announced at a ceremony in Sydney last night. The Australian Museum Eureka Prizes are the country’s most…
Posted: 24 August 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition…